These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

72 related articles for article (PubMed ID: 1828917)

  • 1. Hemodynamic alterations associated with progression of renal allograft injury.
    Bochicchio T; Ron O; Sandoval G; Pérez-Grovas H; Bordes J; Herrera-Acosta J
    Transplant Proc; 1991 Apr; 23(2):1773-4. PubMed ID: 1828917
    [No Abstract]   [Full Text] [Related]  

  • 2. Fosinopril (Staril)--another ACE inhibitor.
    Drug Ther Bull; 1991 Jun; 29(12):48. PubMed ID: 1834450
    [No Abstract]   [Full Text] [Related]  

  • 3. Renal hemodynamics in hypertensive renal allograft recipients: effects of calcium antagonists and ACE inhibitors.
    Grekas D; Dioudis C; Kalevrosoglou I; Alivanis P; Derveniotis V; Tourkantonis A
    Kidney Int Suppl; 1996 Jun; 55():S97-100. PubMed ID: 8743523
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Deterioration of renal function after converting enzyme inhibition in a patient with renal artery stenosis after transplantation.
    Van Son WJ; Donker AJ; Van der Woude FJ; Meijer S; Slooff MJ; Tegzess AM; Van der Slikke LB
    Neth J Med; 1984; 27(1):10-3. PubMed ID: 6324009
    [No Abstract]   [Full Text] [Related]  

  • 5. Fosinopril prevents hyperfiltration and decreases proteinuria in post-transplant hypertensives.
    Bochicchio T; Sandoval G; Ron O; Pérez-Grovas H; Bordes J; Herrera-Acosta J
    Kidney Int; 1990 Nov; 38(5):873-9. PubMed ID: 2148357
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immediate and short-term cardiovascular effects of fosinopril, a new angiotensin-converting enzyme inhibitor, in patients with essential hypertension.
    Oren S; Messerli FH; Grossman E; Garavaglia GE; Frohlich ED
    J Am Coll Cardiol; 1991 Apr; 17(5):1183-7. PubMed ID: 1826120
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Angiotensin-converting enzyme inhibitors after renal transplantation.
    Bravo P; Felgueiras J; Santos C; Oliveira C; Ponce P
    Transplant Proc; 2008 Apr; 40(3):740-2. PubMed ID: 18455003
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers used for the treatment of hypertension appear to be safe in the early posttransplant period.
    Formica RN; Friedman AL; Lorber MI; Bia MJ
    Transplant Proc; 2004 Nov; 36(9):2675-8. PubMed ID: 15621121
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The renin-angiotensin system and renal function in kidney transplantation.
    Mimran A; Mourad G; Ribstein J
    Kidney Int Suppl; 1990 Nov; 30():S114-7. PubMed ID: 2259069
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reversible renal failure during treatment with captopril.
    Farrow PR; Wilkinson R
    Br Med J; 1979 Jun; 1(6179):1680. PubMed ID: 223715
    [No Abstract]   [Full Text] [Related]  

  • 11. Nephroprotection by antihypertensive agents.
    Schmieder RE
    J Cardiovasc Pharmacol; 1994; 24 Suppl 2():S55-64. PubMed ID: 7898095
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Angiotensin-converting enzyme inhibition and renal protection. An assessment of implications for therapy.
    Hollenberg NK; Raij L
    Arch Intern Med; 1993 Nov; 153(21):2426-35. PubMed ID: 8215747
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Progressive reversible kidney insufficiency after blood pressure reduction with captopril].
    Kindler J; Konrads A; Meurer KA; Sieberth HG
    Internist (Berl); 1981 Jun; 22(6):360-3. PubMed ID: 6265394
    [No Abstract]   [Full Text] [Related]  

  • 14. Renal protection in essential hypertension: how do angiotensin-converting enzyme inhibitors compare with calcium antagonists?
    Bauer JH; Reams GP
    J Am Soc Nephrol; 1990 Nov; 1(5 Suppl 2):S80-7. PubMed ID: 16989071
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects on angiotensin-converting enzyme inhibition on renal hemodynamics in renal artery stenosis.
    Levenson DJ; Dzau VJ
    Kidney Int Suppl; 1987 May; 20():S173-9. PubMed ID: 3037167
    [No Abstract]   [Full Text] [Related]  

  • 16. Angiotensin converting enzyme inhibitors and renal function.
    Mimran A; Ribstein J
    J Hypertens Suppl; 1989 Sep; 7(5):S3-9. PubMed ID: 2681604
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reversal of vascular and renal crises of scleroderma by oral angiotensin-converting-enzyme blockade.
    Lopez-Ovejero JA; Saal SD; D'Angelo WA; Cheigh JS; Stenzel KH; Laragh JH
    N Engl J Med; 1979 Jun; 300(25):1417-9. PubMed ID: 220537
    [No Abstract]   [Full Text] [Related]  

  • 18. Short-term renal hemodynamic changes in patients receiving a renal allograft.
    Lavrijssen AT; Gaillard CA; van Kroonenburg MJ; Heidendal GA; de Leeuw PW; van Hooff JP
    Transplantation; 1994 Jun; 57(11):1661-4. PubMed ID: 8009601
    [No Abstract]   [Full Text] [Related]  

  • 19. Progression of renal allograft histology after renal transplantation in recurrent and nonrecurrent immunoglobulin A nephropathy.
    Jeong HJ; Park SK; Cho YM; Kim MS; Kim YS; Choi J; Kim SI; Lim BJ
    Hum Pathol; 2008 Oct; 39(10):1511-8. PubMed ID: 18620732
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Three new ACE inhibitors for hypertension.
    Med Lett Drugs Ther; 1991 Sep; 33(852):83-4. PubMed ID: 1831531
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.